Announcements Trials

Browse Landscape

Phase

Status

Completed 5 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Lung Neoplasms 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Neuroblastoma 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphoma 1 Endometrial Cancer Recurrent 1 Breast Neoplasms 1 Advanced Cancers 1 Adenocarcinoma of Lung 1 ALK or ROS1-positive NSCLC 1

Interventions

pembrolizumab 29 Capecitabine 24 Bevacizumab 23 Cyclophosphamide 22 Gemcitabine 21 Paclitaxel 20 Nivolumab 19 Fluorouracil 19 Docetaxel 18 aldesleukin 17 Leucovorin 17 Irinotecan 17 Oxaliplatin 15 Interleukin-2 14 Radiosurgery 13 Cisplatin 13 Cetuximab 13 fludarabine 12 Carboplatin 12 Albumin-Bound Paclitaxel 11 fludarabine phosphate 10 Ipilimumab 10 Drug Therapy 10 Doxorubicin 10 Sunitinib 9 Radiotherapy 9 Everolimus 9 130-nm albumin-bound paclitaxel 9 Trastuzumab 8 Temozolomide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neoplasm Metastasis × Crizotinib × Clear all

NCT02074878 2017-08-09

CRIZENT

Baylor Breast Care Center

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡